Sanovel

Istanbul, Turkey
VISIT WEBSITE
Sanovel is a leading Turkish pharmaceutical company established in 1983, specializing in the development, manufacture, and marketing of branded generic pharmaceutical products. The company operates a state-of-the-art production and R&D campus in Silivri, Istanbul, and maintains a strong focus on intellectual property, holding numerous patents and maintaining EU GMP and FDA certifications. Sanovel offers a diverse portfolio of over 180 products across various therapeutic areas, including cardiovascular, respiratory, gastrointestinal, and anti-infectives. The company is actively expanding its global footprint through licensing agreements and exports to over 40 countries, while also providing contract development and manufacturing (CDMO) services to international partners.
CLASSIFICATION
Company Type:Biotech
Industry:Pharmaceuticals
Sub-Industry:Branded Generics
SIZE & FINANCIALS
Employees:1001-5000
Founded:1983
Ownership:private
Status:operating
FUNDING
Total Raised:$200M
Investors:Metric Capital
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:PharmaMar (Licensing agreement for marine-derived anticancer drugs)
COMPETITION
Position:Leader
Competitors:Abdi İbrahim, Zentiva, Mustafa Nevzat (Amgen), Koçak Farma, Gen İlaç
LEADERSHIP
Key Executives:
Hülya Yalın - CEO
Mete Türkyılmaz - IT Director
Scientific Founders:Erol Toksöz
LINKS
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Sanovel and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Sanovel. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.